Published in Gene Therapy Weekly, September 9th, 1996
"This antibody is being developed for immunoprophylaxis and immunotherapy of HIV-1 infection in humans," said Paul W.H.I. Parren of The Scripps Research Institute, La Jolla, California.
Parren described development and testing of IgG1 b12 at the XI International Conference on AIDS, held July 7-12, 1996, in Vancouver, British Columbia, Canada.
Parren and colleagues began their search for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.